Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years

Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years

Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr

This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept

Biocon Biologics secures Canada market entry date for YESAFILI

This agreement paves the way for the introduction of YESAFILI into the Canadian market

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

DME market across 7MM set to reach $11.1 billion in 2031, forecasts GlobalData

Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines

Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.

Complement Therapeutics raises €5 million seed financing

Appoints Dr Rafiq Hasan as CEO

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion

The companies will continue with their exclusive agreements, including commercialization of their current portfolio